CONTACT US
Any doubt or in need of clarification?
We are at your service.
CEO: Dr. Silvia D’Alessio
Dr. Silvia D’Alessio earned her Ph.D. in Clinical and Experimental Oncology from the University of Florence in 2004.
From 2004 to 2011, she worked in Professor Francesco Blasi’s laboratory at the San Raffaele Scientific Institute, Division of Genetics and Cell Biology in Milan. There, she focused on the role of the plasminogen activation system in wound healing and cancer, as documented by several publications in the field. Her research explored the function of serine proteases and metalloproteases in disease, tissue remodeling, tumor invasion, and metastasis.
From 2011 to 2020, she worked in Professor Silvio Danese’s laboratory at Humanitas Research Hospital in Rozzano (Milan, IBD Center), studying the role of the lymphatic system in the pathogenesis of chronic inflammatory bowel diseases and colorectal cancer. She also investigated the interactions between the intestinal epithelial barrier and the microbiota in IBD and colorectal cancer, the role of pro-resolving lipid mediators in resolving intestinal inflammation, and the impact of fibrosis in IBD patients.
She gained experience in coordinating preclinical and translational projects in collaboration with pharmaceutical companies, aiming to identify new therapeutic targets and predictors of treatment response. She established industry partnerships and secured funding from pharmaceutical firms, contributing to the testing of novel therapeutic compounds in animal models, ex vivo, and in vitro systems of IBD, intestinal fibrosis, and colorectal cancer.
She founded PhoenixLAB s.r.l.s in July 2020.